CS Diagnostics holder reports 42,560,096 shares

CS Interpharm General Trading Co. LLC filed an initial ownership report showing a large stake in CS Diagnostics Corp. (CSDX).

Rhea-AI Filing Summary

CS Interpharm General Trading Co. LLC filed an initial ownership report showing a large stake in CS Diagnostics Corp. (CSDX). The filing reports beneficial ownership of 42,560,096 shares of CS Diagnostics common stock held directly as of December 31, 2025. No derivative securities such as options or warrants are listed in the report.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider CS Interpharm General Trading Co. LLC

Role 10% Owner

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 42,560,096 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does CS Interpharm’s Form 3 filing reveal about CSDX?

CS Interpharm General Trading Co. LLC reported holding 42,560,096 shares of CS Diagnostics Corp. common stock. This Form 3 is an initial statement of beneficial ownership, indicating CS Interpharm is a 10% owner as of December 31, 2025.

How many CS Diagnostics (CSDX) shares does CS Interpharm own?

CS Interpharm General Trading Co. LLC reported beneficial ownership of 42,560,096 shares of CS Diagnostics common stock. These shares are listed as held directly, making CS Interpharm a significant, over-10% shareholder in the company as of the reported date.

What is the effective date of CS Interpharm’s reported CSDX ownership?

The Form 3 states a date of event of December 31, 2025. This date marks when CS Interpharm General Trading Co. LLC’s reportable beneficial ownership position of 42,560,096 CS Diagnostics common shares is measured for disclosure purposes in the filing.

Does CS Interpharm report any derivative securities in CSDX?

No, the Form 3 for CS Interpharm General Trading Co. LLC shows no derivative securities in Table II. Only common stock is listed, with 42,560,096 shares of CS Diagnostics Corp. common stock reported as directly beneficially owned.

Is CS Interpharm a 10% owner of CS Diagnostics (CSDX)?

Yes. The insider filing identifies CS Interpharm General Trading Co. LLC as a 10% owner of CS Diagnostics Corp. It reports direct beneficial ownership of 42,560,096 common shares, which places the entity above the 10% ownership disclosure threshold.

Who signed the Form 3 reporting CS Interpharm’s CSDX holdings?

The Form 3 is signed “/s/ Mohammad Essayed” dated February 4, 2026. The reporting person, however, is the entity CS Interpharm General Trading Co. LLC, which is listed as the 10% beneficial owner of CS Diagnostics Corp. common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 02:00 PM EST Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

CS Interpharm General Trading Co. LLC

(Last) (First) (Middle)

1603 CAPITOL AVENUE, SUITE 413

(Street)

CHEYENNE WY 82001

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
12/31/2025

3. Issuer Name and Ticker or Trading Symbol
CS DIAGNOSTICS CORP. [ CSDX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	42,560,096	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Mohammad Essayed	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.